Literature DB >> 20189876

Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale.

Anil Bagri1, Hosein Kouros-Mehr, Kevin G Leong, Greg D Plowman.   

Abstract

Several ongoing clinical studies are designed to test the efficacy of antiangiogenic therapies in the adjuvant setting, where the goal is to increase the cure rate in patients who have just undergone surgical resection of all visible disease. Tumors depend on angiogenesis to support their growth and progression and blockade of this process has proven to be a valid strategy for treating multiple types of advanced metastatic cancer. However, results from the first of these clinical adjuvant studies were disappointing, stimulating extensive debate as to the potential of this approach. It will require additional clinical studies before we realize whether the effects of angiogenic blockade are durable, and if they are able to cure a subset of patients with early stage cancer. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20189876     DOI： 10.1016/j.molmed.2010.01.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  32 in total

1.  Vascular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin {alpha}9{beta}1: identification of a specific {alpha}9{beta}1 binding site.

Authors:  Saji Oommen; Shiv K Gupta; Nicholas E Vlahakis
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

2.  Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

Authors:  Harry D Bear; Gong Tang; Priya Rastogi; Charles E Geyer; Qing Liu; André Robidoux; Luis Baez-Diaz; Adam M Brufsky; Rita S Mehta; Louis Fehrenbacher; James A Young; Francis M Senecal; Rakesh Gaur; Richard G Margolese; Paul T Adams; Howard M Gross; Joseph P Costantino; Soonmyung Paik; Sandra M Swain; Eleftherios P Mamounas; Norman Wolmark
Journal:  Lancet Oncol       Date:  2015-08-10       Impact factor: 41.316

3.  Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment.

Authors:  Dong Mao; Yun Zhang; Hang Lu; Hong Zhang
Journal:  Tumour Biol       Date:  2014-05-22

Review 4.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Authors:  John M L Ebos; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

Review 5.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

6.  Inhibition of metastasis of oral squamous cell carcinoma by anti-PLGF treatment.

Authors:  Jingqiu Bu; Xi Bu; Bing Liu; Fei Chen; Peng Chen
Journal:  Tumour Biol       Date:  2014-11-29

Review 7.  Corneal neovascularization: an anti-VEGF therapy review.

Authors:  Jin-Hong Chang; Nitin K Garg; Elisa Lunde; Kyu-Yeon Han; Sandeep Jain; Dimitri T Azar
Journal:  Surv Ophthalmol       Date:  2012-09       Impact factor: 6.048

8.  Molecular regulation of cervical cancer growth and invasion by VEGFa.

Authors:  Baohuan Chen; Chunxiao Zhang; Pingping Dong; Yuanying Guo; Nan Mu
Journal:  Tumour Biol       Date:  2014-08-19

9.  Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling.

Authors:  Lemen Pan; Guanfeng Yu; Xiangjian Chen; Xiaoqiang Li
Journal:  Organogenesis       Date:  2017-09-21       Impact factor: 2.500

Review 10.  Role of angiogenesis in endodontics: contributions of stem cells and proangiogenic and antiangiogenic factors to dental pulp regeneration.

Authors:  Mohammad Ali Saghiri; Armen Asatourian; Christine M Sorenson; Nader Sheibani
Journal:  J Endod       Date:  2015-01-31       Impact factor: 4.171
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.